United States Formulation Development Outsourcing Market Report by Service, Formulation, Therapeutic Area, End Use, States and Company Analysis, 2026-2034

United States Formulation Development Outsourcing Market Size and Forecast 2026-2034

United States Formulation Development Outsourcing Market is expected to reach US$ 19.33 Billion by 2034 from US$ 10.79 Billion in 2025, with a CAGR of 6.69% from 2026 to 2034. Growing pharmaceutical pipelines, increasing complexity of drug formulations, rising R&D costs, demand for faster development timelines, expanding biologics and specialty medicines, CDMO expertise, and pharmaceutical companies’ focus on asset-light operations drive outsourcing.

United States Formulation Development Outsourcing Industry Overview

The United States formulation development outsourcing industry is expanding as pharmaceutical and biopharmaceutical companies increasingly rely on specialized contract development and manufacturing organizations (CDMOs) to accelerate drug development, manage technical complexity, and reduce internal infrastructure requirements. Formulation development outsourcing covers preformulation studies, excipient selection, drug-product development, dosage-form optimization, analytical development, stability testing, scale-up, process development, and clinical manufacturing support. Providers increasingly offer integrated services spanning early development through commercial production, allowing sponsors to reduce technology-transfer requirements and improve development continuity. Demand is generated by conventional small-molecule medicines as well as biologics, highly potent compounds, complex injectable products, modified-release formulations, and other specialized therapies. Increasing pipeline complexity is encouraging pharmaceutical companies to access external formulation scientists, specialized equipment, and established regulatory expertise.

Technological advancement is further broadening outsourcing opportunities. CDMOs are investing in advanced drug-delivery technologies, particle engineering, spray drying, sterile fill-finish, high-potency manufacturing, biologics capabilities, and formulation platforms designed to improve bioavailability and product performance. In September 2026, Lonza announced plans to construct a large-scale commercial spray-drying facility in Bend, Oregon, strengthening its U.S. particle-engineering and bioavailability-enhancement capabilities. The facility is expected to be completed in 2029 and create more than 80 jobs. In June 2026, Recipharm announced a multi-million-dollar expansion of its U.S. sterile manufacturing footprint to increase capabilities supporting biologics and advanced therapies, including fill-finish and lifecycle development services. These investments demonstrate growing demand for specialized formulation and drug-product development capabilities within the domestic outsourcing ecosystem.

The U.S. market is also influenced by pharmaceutical supply-chain resilience and increasing emphasis on domestic manufacturing. In February 2026, the FDA launched its PreCheck Pilot Program to facilitate new domestic pharmaceutical manufacturing facilities and increase regulatory predictability. By June 2026, the agency had selected seven companies for the program, aiming to expand U.S. production capacity and strengthen supply-chain resilience. Meanwhile, CDMOs continue expanding strategic relationships with pharmaceutical and biotechnology companies. Lonza announced an expanded collaboration with a U.S. biopharmaceutical company in July 2026 covering additional biologics programs and development and manufacturing solutions. Consequently, the industry is moving toward integrated outsourcing partnerships that combine formulation development, analytical services, clinical manufacturing, scale-up, and commercial supply.

Growth Drivers for the United States Formulation Development Outsourcing Market

Complex Drug Pipelines Encourage Specialized External Expertise

The increasing complexity of pharmaceutical pipelines is one of the strongest drivers of formulation development outsourcing. Drug developers are advancing highly potent compounds, poorly soluble molecules, controlled-release products, peptides, biologics, and other therapies requiring specialized formulation approaches. Developing these products internally can require expensive equipment, highly trained scientists, specialized containment infrastructure, and extensive analytical capabilities. Outsourcing enables sponsors to access established formulation platforms and experienced technical teams without making equivalent capital investments. CDMOs can support excipient screening, solubility enhancement, particle engineering, dosage-form selection, stability evaluation, analytical development, and scale-up. The trend is particularly important for smaller biotechnology companies that may possess promising drug candidates but lack extensive development infrastructure. Outsourcing also allows larger pharmaceutical companies to supplement internal capabilities when pipelines expand or specialized technologies are required. As drug development becomes increasingly technically demanding, external formulation partners can provide flexible capacity, specialized knowledge, and integrated development pathways, supporting continued outsourcing adoption.

Demand for Faster Development Timelines Supports Integrated CDMO Partnerships

Pharmaceutical companies face significant pressure to advance promising candidates from discovery into clinical development and commercialization efficiently. Formulation challenges can delay development when drug candidates exhibit poor solubility, instability, low bioavailability, manufacturing difficulties, or unfavorable dosage characteristics. Experienced CDMOs can accelerate these activities by combining formulation scientists, analytical laboratories, process-development teams, manufacturing infrastructure, and regulatory expertise under one outsourcing relationship. Integrated service models can reduce handoffs between vendors and facilitate technology transfer from laboratory-scale development through clinical and commercial manufacturing. Recent investments by U.S. CDMOs illustrate this direction. Recipharm's 2026 U.S. expansion is intended to support development, scale-up, clinical manufacturing, and commercial supply for biologics and advanced therapies. Lonza's U.S. investments similarly expand specialized capabilities such as spray drying and particle engineering. As sponsors prioritize speed-to-market and development flexibility, integrated outsourcing partnerships are increasingly attractive for reducing technical bottlenecks.

Asset-Light Strategies and Domestic Supply-Chain Priorities

Pharmaceutical companies increasingly seek flexible operating models that allow them to access specialized manufacturing and formulation capabilities without owning every development and production asset. Outsourcing converts some fixed infrastructure requirements into variable service expenditure while enabling companies to access technologies that may be required only periodically. This approach is particularly attractive to emerging biotechnology companies with limited capital resources and virtual development models. At the same time, U.S. pharmaceutical supply-chain resilience has become an important strategic consideration. The FDA's PreCheck Pilot Program, launched in February 2026, is designed to facilitate new domestic pharmaceutical manufacturing facilities and increase regulatory predictability. The program received more than 80 participation requests during its initial application period, demonstrating strong industry interest. Greater emphasis on domestic capacity can encourage pharmaceutical sponsors to partner with U.S.-based CDMOs for formulation development, scale-up, manufacturing, and drug-product supply, supporting continued outsourcing demand.

Challenges in the United States Formulation Development Outsourcing Market

Regulatory Complexity and Technology-Transfer Risks

Formulation development outsourcing involves significant regulatory, quality, technical, and documentation requirements. Pharmaceutical sponsors must ensure that external partners operate according to applicable current Good Manufacturing Practice standards and maintain appropriate controls over materials, processes, analytical methods, stability programs, and manufacturing records. Technology transfer between a sponsor and CDMO can also create risks when formulation knowledge, process parameters, analytical methods, or proprietary technologies are transferred between organizations. Differences in equipment, operating procedures, data systems, and technical expertise may complicate scale-up or commercial manufacturing. Changes introduced during formulation optimization must also be appropriately documented and evaluated to ensure product quality and regulatory compliance. Complex biologics, sterile products, and highly potent medicines can introduce additional containment and process requirements. FDA oversight remains extensive across outsourcing and pharmaceutical manufacturing operations, with registered facilities subject to inspection and compliance expectations. Consequently, sponsors must carefully evaluate CDMO capabilities, quality systems, technical expertise, regulatory history, and technology-transfer procedures before establishing long-term partnerships.

Capacity Constraints, Costs, and Dependence on External Partners

Although outsourcing can reduce internal infrastructure requirements, dependence on external providers introduces commercial and operational risks. High-demand CDMOs may face limited capacity for specialized technologies, particularly sterile manufacturing, high-potency compounds, advanced drug delivery, biologics, and sophisticated formulation platforms. Sponsors can therefore encounter longer project queues or higher service costs when specialized capabilities are concentrated among a limited number of providers. Contract pricing can also increase when projects require customized equipment, complex analytical testing, specialized containment, or extensive development work. Supply-chain disruptions affecting active pharmaceutical ingredients, excipients, packaging components, and specialized manufacturing materials can further affect project schedules. The sponsor must also manage intellectual-property protection and maintain effective communication across organizational boundaries. Recent industry investments demonstrate that providers are responding to growing demand by expanding capacity, including Evonik's planned US$100 million investment in its Indiana drug-substance CDMO facility. Nevertheless, capacity availability, project economics, and supplier dependency remain important challenges.

California Formulation Development Outsourcing Market - Biotechnology and Innovation Hub

California is one of the most attractive U.S. markets for formulation development outsourcing because of its large biotechnology ecosystem, pharmaceutical research base, venture-capital activity, and concentration of innovative drug developers. San Diego, San Francisco, Los Angeles, and surrounding life-sciences clusters support extensive R&D across small molecules, biologics, cell and gene therapies, and specialty medicines. Emerging biotechnology companies frequently require external formulation, analytical development, clinical manufacturing, and scale-up expertise because they may not maintain extensive internal infrastructure. California's sophisticated research institutions and specialized CDMOs create opportunities for collaborative development and technology transfer. Demand is particularly strong for complex formulations, injectable products, biologics, and advanced drug-delivery technologies. The state's large pharmaceutical-development ecosystem also encourages long-term outsourcing relationships as candidates move from preclinical work into clinical trials. However, high operating costs, labor expenses, facility costs, and regulatory requirements can increase outsourcing project budgets and influence provider selection.

Texas Formulation Development Outsourcing Market - Expanding Life-Sciences Capacity

Texas has become an increasingly important market for formulation development outsourcing due to its expanding biotechnology sector, large healthcare ecosystem, growing pharmaceutical activity, and comparatively broad industrial infrastructure. Major hubs including Houston, Dallas-Fort Worth, Austin, and San Antonio support pharmaceutical research, biotechnology development, medical innovation, and clinical programs. Smaller and emerging drug developers can benefit from outsourcing formulation development rather than establishing expensive specialized facilities internally. Demand encompasses preformulation, analytical development, oral solid dosage optimization, sterile formulations, biologics, and clinical manufacturing support. Texas also benefits from its transportation infrastructure and large labor market, which can support pharmaceutical supply-chain activities. Universities and research institutions contribute scientific capabilities and partnerships with biotechnology companies. As pharmaceutical manufacturing and life-sciences investment expand, demand for external development services can increase. Challenges include competition for specialized scientific talent, uneven concentration of advanced CDMO capabilities, and the capital requirements associated with highly complex formulation technologies.

New York Formulation Development Outsourcing Market - Research-Driven Pharmaceutical Ecosystem

New York represents a significant formulation development outsourcing market because of its concentration of pharmaceutical companies, biotechnology startups, academic institutions, hospitals, and research organizations. New York City and surrounding life-sciences clusters generate demand for drug-development services across oncology, immunology, rare diseases, neurological disorders, and other therapeutic areas. Biotechnology companies frequently outsource formulation development and clinical manufacturing to specialized CDMOs to conserve capital and accelerate candidate advancement. The state's research-intensive environment supports innovation in drug delivery, biologics, oral formulations, injectable products, and advanced pharmaceutical technologies. Partnerships between academic researchers, emerging biotechnology companies, pharmaceutical developers, and external service providers create opportunities for early-stage formulation projects. New York's access to investment capital and highly skilled scientific professionals further supports outsourcing demand. However, high real-estate, labor, and operating costs can increase project expenses. Sponsors may therefore balance the advantages of New York's innovation ecosystem against cost considerations when selecting formulation development partners.

Florida Formulation Development Outsourcing Market - Growing Pharmaceutical Services Base

Florida's formulation development outsourcing market is supported by its expanding healthcare sector, pharmaceutical services ecosystem, biotechnology activity, and growing population. Miami, Tampa, Orlando, Jacksonville, and other metropolitan areas provide research, healthcare, manufacturing, and laboratory capabilities that can support pharmaceutical development. Outsourcing opportunities include formulation screening, analytical development, oral dosage-form development, sterile products, clinical manufacturing, and specialized drug-delivery services. Florida's expanding life-sciences environment can attract biotechnology companies seeking cost-effective access to development and manufacturing infrastructure. Its geographic position and transportation network can also support distribution and supply-chain activities. The state has an established presence of pharmaceutical and compounding outsourcing facilities, with FDA's September 2026 registered-facility database listing multiple Florida-based facilities. Continued investment in pharmaceutical infrastructure can encourage greater demand for specialized development partners. Nevertheless, advanced formulation projects may still require access to highly specialized equipment, technical expertise, and regulatory capabilities concentrated in larger life-sciences hubs.

Formulation Development Services - From Preformulation to Commercial Readiness

The Formulation Development Market represents the core service area within pharmaceutical outsourcing, encompassing preformulation, excipient selection, compatibility studies, solubility enhancement, dosage-form design, process optimization, analytical development, stability assessment, and scale-up. Outsourcing providers help pharmaceutical and biotechnology companies transform active pharmaceutical ingredients into stable, manufacturable, patient-friendly drug products. Demand is increasing as drug candidates become more complex and sponsors seek specialized technologies without building extensive internal facilities. Formulation providers increasingly offer integrated development models that connect laboratory studies with clinical manufacturing and commercial scale-up. Advanced approaches such as spray drying, particle engineering, controlled release, amorphous solid dispersions, lipid-based systems, and specialized delivery technologies can address bioavailability and stability challenges. Lonza's planned Bend, Oregon facility illustrates increasing investment in particle engineering and spray-drying capabilities within the U.S. CDMO market. The segment's future growth will depend on complex pipelines, speed-to-clinic requirements, and demand for specialized formulation expertise.

Oral Drug Products - High-Volume and Technology-Rich Development

The Oral Market remains a major formulation outsourcing segment because tablets, capsules, oral liquids, and modified-release products represent widely used pharmaceutical dosage forms. Oral formulation development can involve solubility enhancement, bioavailability improvement, taste masking, controlled release, excipient optimization, tablet compression, capsule filling, and stability testing. Many active pharmaceutical ingredients present formulation challenges such as poor water solubility or limited absorption, encouraging sponsors to use specialized CDMO technologies. Oral products are also attractive to patients and manufacturers because of established administration routes, manufacturing infrastructure, and extensive regulatory experience. Outsourcing providers can support projects from early formulation screening through clinical batch production and commercial scale-up. Increasing development of highly potent small molecules and specialty medicines is creating additional technical requirements for containment and process control. As pharmaceutical pipelines continue expanding, sponsors increasingly use external partners to access advanced oral formulation technologies while reducing internal capital expenditure and shortening development timelines.

Infectious Diseases - Formulation Support for Complex Therapeutic Pipelines

The Infectious Diseases Market represents an important application area for formulation development outsourcing, covering medicines intended to prevent or treat bacterial, viral, fungal, parasitic, and other infectious conditions. Drug developers may outsource formulation development when projects require specialized delivery systems, improved stability, enhanced bioavailability, pediatric dosage forms, sterile preparations, or scalable manufacturing processes. Infectious-disease products can include oral solid doses, oral liquids, injectables, inhaled therapies, and other dosage forms. Formulation requirements can vary substantially depending on the active ingredient, target population, treatment duration, and desired route of administration. Outsourcing provides access to formulation scientists, analytical laboratories, process-development teams, and clinical manufacturing capabilities without requiring sponsors to build dedicated facilities. Demand can also arise from emerging pathogens and the need to accelerate development programs. Providers with flexible capacity and established quality systems can help pharmaceutical companies advance infectious-disease candidates while addressing regulatory, stability, manufacturing, and scale-up requirements.

Pharmaceutical and Biopharmaceutical Companies - Principal Outsourcing Customers

The Pharmaceutical and Biopharmaceutical Companies Market represents the principal customer base for formulation development outsourcing services. Large pharmaceutical companies use external providers to supplement internal capabilities, access specialized technologies, manage capacity fluctuations, and accelerate selected development programs. Biotechnology companies frequently depend even more heavily on CDMOs because early-stage organizations may lack formulation laboratories, manufacturing facilities, analytical infrastructure, or specialized personnel. Outsourcing demand spans small molecules, biologics, peptides, highly potent compounds, sterile products, oral formulations, and advanced drug-delivery systems. Sponsors increasingly favor integrated partners capable of supporting development from preformulation through clinical and commercial manufacturing. Lonza's July 2026 expansion of its collaboration with a U.S. biopharmaceutical company, covering additional biologics programs and broader development and manufacturing services, illustrates this relationship model. As pharmaceutical pipelines diversify and development timelines remain commercially important, companies are expected to continue outsourcing specialized activities while retaining strategic control over intellectual property, clinical strategy, and product commercialization.

Market Segmentations

Service

• Formulation Development
• Preformulation

Formulation

• Oral
• Injectable 
• Others

Therapeutic Area

• Oncology
• Infectious Diseases
• Neurology
• Hematology
• Respiratory
• Cardiovascular
• Dermatology
• Others

End Use

• Pharmaceutical and Biopharmaceutical Companies
• Government and Academics Institutes
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All the Key players have been covered

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• SGS S.A.
• Intertek Group plc
• Recipharm
• Lonza
• Charles River Laboratories International, Inc
• Eurofins Scientific SE
• Labcorp
• Thermo Fisher Scientific, Inc.

Report Details: